Company intelligence / Profile preview

Eyecure Therapeutics Inc.

Wuxi City, Jiangsu Province, Chinaorpha.net ↗

Ownership: Private
Development stage: Phase 1

Overview

Eyecure Therapeutics Inc. develops cell therapies using human retinal pigment epithelial cells targeting inherited retinal disorders such as retinitis pigmentosa and Leber congenital amaurosis. Their lead program has reached early clinical development in China, with orphan drug status in the United States. The company holds patents related to RPE cell processing technologies but has not yet reported published clinical results.

Therapeutic areas: Ophthalmology
Modalities: Cell therapy
Industry: Biotech

Drug pipeline

1 asset

Human RPE cells

Phase 1

Indications: Leber congenital amaurosis, Early-onset severe retinal dystrophy

Partnerships

Chengdu Kanghong Pharmaceuticals Group Co., Ltd.

Beyond the preview

Go deeper on Eyecure Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eyecure Therapeutics Inc..

Explore the full profile